05Y Stock Chart & Stats
€1.63
-€0.01(-0.49%)
At close: 4:00 PM EST
€1.63
-€0.01(-0.49%)
Day’s Range― - ―
52-Week Range€1.02 - €1.78
Previous CloseN/A
Volume200.00
Average Volume (3M)482.00
Market Cap
€36.13M
Enterprise Value€35.14
Total Cash (Recent Filing)€5.62M
Total Debt (Recent Filing)€108.00K
Price to Earnings (P/E)―
Beta0.19
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding29,614,338
10 Day Avg. Volume872
30 Day Avg. Volume482
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)8.11
Price to Sales (P/S)0.00
P/FCF Ratio-4.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.38
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pipeline & Oral Small-Molecule FocusVivoryon's concentrated pipeline centers on oral small-molecule therapeutics that target disease-relevant pathways in neurodegeneration and inflammation. A focused, development-stage asset base can attract partners, create strategic optionality, and underpin long-term commercial potential if clinical milestones are met.
Low LeverageMinimal debt reduces fixed financial obligations and lowers insolvency risk, preserving strategic flexibility for financing choices. For a clinical-stage biotech, low leverage supports the ability to pursue partnerships or equity funding without heavy interest burdens, a durable structural advantage.
Improving Cash Burn TrendA meaningful reduction in operating cash burn year-over-year signals improving spending discipline or program prioritization. Sustained improvement in cash consumption can extend runway and reduce near-term financing pressure, aiding execution of clinical programs over the coming months.
Bears Say
No Recent RevenueAbsence of product revenue leaves the company reliant on external financing and milestone income to fund operations. Without recurring revenue, long-term sustainability depends on successful clinical progress or partner deals, increasing investor exposure to development risk.
Shrinking Equity BaseA sharply reduced equity base and contracting assets materially weaken financial flexibility. This structural deterioration raises the likelihood of dilutive financing, constrains capacity to fund R&D internally, and heightens execution risk for multi-phase clinical programs.
Persistent Negative Cash FlowConsistently negative operating and free cash flow indicate ongoing cash consumption from R&D without offsetting inflows. Over months this necessitates external funding, which can be dilutive or uncertain, and represents a structural constraint on advancing pipeline programs independently.
Vivoryon Therapeutics AG News
05Y FAQ
What was Vivoryon Therapeutics AG’s price range in the past 12 months?
Vivoryon Therapeutics AG lowest stock price was €1.01 and its highest was €1.78 in the past 12 months.
What is Vivoryon Therapeutics AG’s market cap?
Vivoryon Therapeutics AG’s market cap is €36.13M.
When is Vivoryon Therapeutics AG’s upcoming earnings report date?
Vivoryon Therapeutics AG’s upcoming earnings report date is Aug 06, 2026 which is in 15 days.
How were Vivoryon Therapeutics AG’s earnings last quarter?
Currently, no data Available
Is Vivoryon Therapeutics AG overvalued?
According to Wall Street analysts Vivoryon Therapeutics AG’s price is currently Overvalued.
Does Vivoryon Therapeutics AG pay dividends?
Vivoryon Therapeutics AG does not currently pay dividends.
What is Vivoryon Therapeutics AG’s EPS estimate?
Vivoryon Therapeutics AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vivoryon Therapeutics AG have?
Vivoryon Therapeutics AG has 29,614,338 shares outstanding.
What happened to Vivoryon Therapeutics AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Vivoryon Therapeutics AG?
Currently, no hedge funds are holding shares in DE:05Y
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vivoryon Therapeutics AG
Vivoryon Therapeutics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel treatments for Alzheimer's disease. The company's therapeutic pipeline primarily focuses on mitigating Alzheimer's by targeting and preventing the formation of toxic pyroglutamate-Abeta (pGlu-Abeta). Its flagship compound, PQ912, a small molecule QC inhibitor, has successfully concluded Phase IIb clinical trials for both Alzheimer's disease and various cancer indications. Additionally, Vivoryon is advancing PQ1565, another small molecule (a glutaminyl-peptide cyclotransferase-like inhibitor), through preclinical development, specifically for cancer therapy. Beyond its small molecule programs, the company is also developing a monoclonal antibody designed to improve the clearance of pGlu-Abeta from the body. To bolster its research and development efforts, Vivoryon has forged several key partnerships, including collaborations with the University Medical Center Schleswig-Holstein for cancer immunotherapy discovery, Nordic Bioscience for the clinical progression of PQ912 in Alzheimer's, and the Fraunhofer Institute for cell therapy and immunology. Furthermore, a significant regional licensing agreement with Simcere Pharmaceutical Group Ltd. aims to develop and commercialize treatments for Alzheimer's disease by targeting the neurotoxic amyloid species N3pE (pGlu-Abeta). Established in 1997, Vivoryon Therapeutics N.V. maintains its headquarters in Halle, Germany.